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Lower Body Mass Index and Atrial Fibrillation as Independent Predictors 
for Mortality in Patients with Implantable Cardioverter Defibrillator
Aim To evaluate risk factors related to total mortality in an unselected 
population of patients implanted with a cardioverter defibrillator.
Methods Survival analysis was performed retrospectively investigat-
ing the records of 77 consecutive patients implanted with defibrilla-
tors (median 67 years, range 38-83 years; 63 men). All patients were 
followed regularly in 3-month intervals. The cause of mortality was 
examined clinically, including post-mortem examination of device to 
assess possible arrhythmogenic death. Predictors were evaluated by Ka-
plan-Meier analysis with log-rank tests and by Cox regression analysis 
(proportional hazards).
Results Defibrillator recipients had a mean (±standard deviation) 
ejection fraction of 34 ± 13%, left ventricular end-diastolic dimension 
(LVEDD) of 6.24 ± 0.8 cm, QRS duration of 129 ± 34 ms, and body 
mass index (BMI) of 26.4 ± 4.3 kg/m2. Atrial fibrillation was present 
in 32 patients, paroxysmal fibrillation in 23, and permanent fibrillation 
in 9 patients. The estimate of mean survival time for all patients was 
51.5 (95% confidence interval 46.6-56.5) months. During the study pe-
riod 11/77 (14%) patients died. Mean follow-up time was 24.5 months 
(range 0.2-60.7) for survivors and 7.6 months (range 1.5-42) for non-
survivors. Independent predictors of mortality were the NYHA class 
(P = 0.004), BMI≤26 kg/m2 (P = 0.024), presence of paroxysmal or 
permanent atrial fibrillation (P = 0.014), and absence of arterial hy-
pertension (P = 0.010). LVEDD showed a weak significant effect on 
survival (P = 0.049).
Conclusion Patients with implantable cardioverter defibrillator and 
a normal to lower BMI or atrial fibrillation had a significantly higher 
overall mortality. These factors may be indicative of end stage heart fail-
ure or diseases associated with high sympathetic activation.
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Patients with implantable cardioverter defibril-
lator, in addition to an intrinsic residual risk of 
sudden cardiac death due to a reduced effective-
ness of defibrillators, have a high incidence of 
co-morbidities, which increase mortality in this 
population. Several studies have demonstrated 
that the implantation of a cardioverter defibril-
lator for both secondary and primary prevention 
significantly reduces total mortality by prevent-
ing sudden cardiac death (1-3). However, the 
death rate from non-arrhythmic causes among 
patients with implantable cardioverter defibril-
lator is substantial (4) and deserves further in-
vestigation. The purpose of this study was to in-
vestigate various risk factors with respect to total 
mortality in an unselected population of patients 
with implanted cardioverter defibrillator devices.
Subjects and methods
Subjects
We followed-up clinical characteristics of 77 pa-
tients (median age 67 years, range 38-83 years; 63 
men and 14 women) who received an implant-
able cardioverter defibrillator at our institution 
between 2001 and 2005. All patients gave writ-
ten informed consent for implantation of the de-
vice. The survival analysis was carried out retro-
spectively investigating the records of the patients 
implanted with defibrillators. Treatment with an 
implantable cardioverter defibrillator was indi-
cated for secondary prevention of sudden death 
in 72 patients. Ventricular tachycardia was docu-
mented in 51 (66%) and ventricular fibrillation 
in 21 (27%) patients. An implantable cardiovert-
er defibrillator was inserted for prophylactic in-
dication in 5 patients based on the MADIT-II 
criteria (2). Single-chamber implantable cardio-
verter defibrillator was implanted in 43 patients, 
dual-chamber implantable cardioverter defibril-
lator in 29 patients, and cardiac-resynchroni-
zation defibrillator in 5 patients with advanced 
heart failure. Patients with no indications for an-
tibradycardia pacing received a single-chamber 
defibrillator (n = 41), which was programmed to 
back up pacing at a lower rate limit of 40 beats 
per minute in order to avoid right ventricular 
pacing. In 13 patients, a dual-chamber defibrilla-
tor was implanted, mainly for enhanced discrim-
ination of atrial from ventricular arrhythmias, 
but programmed to dual chamber pacing/dual 
chamber sensing/inhibited response to sensing 
(DDI) back-up mode. In patients with indica-
tions for dual chamber pacing, defibrillators were 
programmed either to dual chamber pacing/
dual chamber sensing/dual response to sensing-
rate modulation (DDDR) mode at a lower rate 
limit of 60 beats per minute in 9 patients or to 
a functional atrial pacing/atrial sensing/inhibit-
ed response to sensing-rate modulation (AAIR) 
mode in 7 patients favoring intrinsic ventricu-
lar conduction. Only 2 patients with permanent 
atrial fibrillation were set to a lower rate limit of 
60 beats per minute in ventricular pacing/ven-
tricular sensing/inhibited response to sensing-
rate modulation (VVIR) mode.
Methods
Clinical assessment of co-morbidities and weight 
and height measurement were performed at the 
time of device implantation. At this stage, all 
ICD recipients were without any signs of overt 
heart failure. Body mass index (BMI) was cal-
culated as weight in kilograms divided by the 
square of height in meters. Hypertension was de-
fined by systolic and/or diastolic blood pressure 
≥130 and/or ≥85 mm Hg or if the patient was 
receiving antihypertensive medications. Resting 
heart rate was derived from surface electrocar-
diogram (ECG), recorded before device implan-
tation. Atrial fibrillation was defined as a history 
of electrocardiographically documented parox-
ysmal or permanent atrial fibrillation. Renal in-
sufficiency was defined by baseline creatinine 
concentration of ≥132 µmol/L. Diabetes melli-
tus was defined by a fasting plasma glucose level 
of ≥7 mmol/L or if the patient was undergoing 
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antidiabetic treatment. Diagnosis of chronic ob-
structive pulmonary disease was based on abnor-
mal spirometry results. A history of myocardial 
infarction was defined as a previous cardiac event 
with elevated peak creatine kinase-MB fraction 
and/or new electrocardiographic changes sug-
gestive of acute myocardial infarction. After car-
dioverter defibrillator implantation, all patients 
were followed on a regular 3-month basis at our 
outpatient clinic. The primary cause of death re-
fers to the event that led to death. Mode of death 
was assessed clinically. In addition, defibrillator 
devices were examined to establish whether the 
cause of death was arrhythmogenic or non-ar-
rhythmogenic. Overall, the deaths were classified 
as cardiac or non-cardiac.
Statistical analysis
Analyses were performed using the Statisti-
cal Package for the Social Sciences, version 12.0 
(SPSS Inc., Chicago, IL, USA) and PEPI 4.0 
software (Salt Lake City, UT, USA). Character-
istics of subjects were presented as medians and 
range or as means and standard deviations. Kol-
mogorov-Smirnov test was used to check the 
normal distribution of data. Unpaired t tests 
or Mann-Whitney test were used for compari-
son of continuous variables and Fisher exact test 
was used for nominal parameters. Survival curves 
were generated by the Kaplan-Meier procedure 
and compared using the log-rank test. Significant 
variables affecting the outcome were incorporat-
ed into a multivariate Cox proportional-hazards 




The baseline clinical characteristics of the pa-
tient cohort are summarized in Table 1 (5,6). 
Mean ejection fraction was 34 ± 13%, mean 
QRS duration 129 ± 34, and median BMI 26.1 
kg/m2 (range 17.3–40.1). For survivors medi-
an BMI was 26.6 kg/m2 (range 19.5-40.1) and 
24.0 kg/m2 (range 17.3-30.1) for non-survivors 
(Figure 1). Non-survivors had significantly low-
er BMI (P = 0.015), higher NYHA functional 
class (P = 0.014), greater LVEDD (P = 0.008), 
and higher prevalence of atrial fibrillation 
(P = 0.007). Notably, only 2 out of 11 (18%) pa-
tients in the non-survivor group had a history 
of arterial hypertension, compared with 40 out 
of 66 (61%) in the survivor group (P = 0.014) 
There were no significant differences in the use of 
amiodarone, beta blocker, or lipid lowering drug 
therapy. Device examination revealed appropri-
ate antitachycardia pacing and/or shock therapy 
in 43 (56%) patients, but there were no differ-
ences between survivors and non-survivors. Pa-
tients receiving appropriate discharges had lower 
BMI than patients without defibrillator thera-
pies (25.1 kg/m2, range 19.5-36.3 vs 27.4 kg/m2, 
range 17.3-40.1, respectively; P = 0.096). Inap-
propriate shocks were delivered to 9 patients (8 
survivors and 1 non-survivor) because of rapid-
ly conducted supraventricular tachycardias and 
lead fracture in 1 patient. Inadequate defibrilla-
tor therapies were more frequent in patients with 
single-chamber than dual-chamber devices(6/43 
vs 3/29 patients, respectively; P = 0.262).
Figure 1. Distribution of the body mass index (BMI) among the survi-
vors (n = 66) and non-survivors (n = 11). Mean BMI (±standard devia-
tion) was 26.9 ± 4.3 kg/m2 for survivors (closed bars), and 23.5 ± 3.5 
kg/m2 for non-survivors (open bars).
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Follow-up data
Overall, more than a half of patients were re-hos-
pitalized during the follow-up, mostly due to 
progression of heart failure. During the study pe-
riod, 11 out of 77 patients (14%) died. Median 
follow up time was 24.5 months (range 0.2-60.7) 
for survivors and 7.6 months (range 1.5-42) for 
Table 1. Clinical baseline characteristics of the patients with implantable cardioverter defibrillator according to survival
Patients
Variable* total (n = 77) survivors (n = 66) non-survivors (n = 11) P†
Age, years (range) 66 (38-83) 66 (38-83) 67 (46-80) 0.839
Male/female, No. (%) 63/14 (82/18) 54/12 9/2 1.000
Body mass index, kg/m2 26.4 ± 4.3 26.9 ± 4.3 23.5 ± 3.5 0.015
Ejection fraction, %   34 ± 13   35 ± 14   30 ± 7 0.127
Left ventricular end-diastolic dimension, cm 6.24 ± 0.8 6.14 ± 0.8 6.86 ± 0.7 0.008
Mitral regurgitation, No. (%): 0.136
 none  9 (12)  8 (10)  1 (1)
 mild 43 (56) 38 (49)  5 (6)
 moderate 22 (28) 19 (25)  3 (4)
 severe  3 (4)  1 (1)  2 (3)
Heart rate, beats per minute 69.9 ± 11.1 69.7 ± 10.7 70.6 ± 13.9 0.804
QRS duration, ms  129 ± 34  127 ± 34  137 ± 27 0.351
NYHA functional class, No. (%):‡ 0.014
 I 15 (20) 15 (20)  0
 II 35 (45) 31 (40)  4 (5)
 III 22 (29) 18 (23)  4 (5)
 IV  5 (6)  2 (3)  3 (4)
Etiology, No. (%): 0.281
 ischemic cardiomyopathy 50 (65) 43 (56)  7 (9)
 non-ischemic cardiomyopathy 17 (22) 13 (17)  4 (5)
 idiopathic dilated cardiomyopathy 15 (19) 15 (19)  0
 valvular cardiomyopathy  2 (3)  1 (1)  1 (1)
 cardiac arrhythmias 10 (13) 10 (13)  0
Indication, No. (%): 0.275
 ventricular fibrillation 21 (27) 20 (26)  1 (1)
 ventricular tachycardia 51 (66) 41 (53) 10 (13)
 primary prevention  5 (6)  5 (6)  0
Device type, n (%):§ 0.303
 single-chamber 43 (56) 39 (51)  4 (5)
 dual-chamber 29 (38) 23 (30)  6 (8)
 cardiac resynchronization device  5 (6)  4 (5)  1 (1)
Pacing mode, No. (%):§ 0.016
 VVI or DDI – back-up pacing mode 54 (70) 50 (65)  4 (5)
 DDDR  9 (12)  5 (6)  4 (5)
 AAIR  7 (9)  6 (8)  1 (1)
 VVIR  2 (3)  1 (1)  1 (1)
 Biventricular pacing  5 (6)  4 (5)  1 (1)
Atrial fibrillation, No. (%): 0.007
 permanent  9 (12)  6 (8)  3 (4)
 paroxysmal 23 (30) 17 (22)  6 (8)
 none 45 (58) 43 (56)  2 (3)
History of myocardial infarction, No. (%) 43 (56) 36 (47)  7 (9) 0.634
Coronary revascularization (CABG/PCI), No. (%) 31 (40) 28 (36)  3 (4) 0.422
Diabetes, No. (%) 11 (14) 10 (13)  1 (1) 0.826
Renal dysfunction, No. (%) 10 (13)  8 (10)  2 (3) 0.485
Obstructive lung disease, No. (%) 13 (17) 11 (14)  2 (3) 0.839
Arterial hypertension, No. (%) 42 (55) 40 (52)  2 (3) 0.014
Antiarrhythmic medication, No. (%): 0.489
 beta blocker 24 (31) 21 (27)  3 (4)
 amiodarone 10 (13)  7 (9)  3 (4)
 beta blocker + amiodarone 34 (44) 30 (39)  4 (5)
 no antiarrhythmic drug  9 (12)  8 (10)  1 (1)
Lipid lowering drug 31 (40) 28 (36)  3 (4) 0.422
Defibrillator therapy (ATP and/or shock), No. (%) 43 (56) 34 (44)  9 (12) 0.758
*Abbreviations: NYHA – New York Heart Association; CABG – coronary artery bypass graft; PCI – percutaneous coronary intervention; ATP – antitachycardia pacing; VVIR – ventricu-
lar pacing-ventricular sensing-inhibited response to sensing-rate modulation; AAIR – atrial pacing-atrial sensing-inhibited response to sensing-rate modulation; DDDR – dual chamber 
pacing-dual chamber sensing-dual response to sensing-rate modulation; DDI – dual chamber pacing-dual chamber sensing-inhibited response to sensing.
†χ2 test or Fisher exact test for nominal characteristics, t-test or Mann-Whitney test for continuous characteristics.
‡According to theNew York Heart Association Classification (5).
§According to the NASPE/BPEG generic pacemaker code for antibradyarrhythmia and adaptive-rate pacing and antitachyarrhythmia devices (6).
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non-survivors. Kaplan-Meier estimates of the 
1, 2, 3, and 4-year cumulative probability of sur-
vival were 90%, 86%, 83%, and 77%, respective-
ly. The estimate of mean survival time for all pa-
tients was 51.5 (95% confidence intervals [CI] 
46.6-56.5) months.
Risk factors for mortality
Using Kaplan-Meier estimates of survival, the 
following variables showed a significant impact 
on survival (Table 2): BMI (P = 0.024), atrial fi-
brillation (P = 0.014), NYHA class (P = 0.004), 
LVEDD (P = 0.049), and a negative history of 
arterial hypertension (P = 0.010). The Kaplan-
Meier survival curves for BMI below and above 
the median (26.1 kg/m2) and for the presence 
of atrial fibrillation – either in the paroxysmal 
or the permanent form – are shown in Figure 2. 
QRS duration ≥120 ms at the time of cardiovert-
er defibrillator implantation did not reach statis-
tical significance (P = 0.072). No significant dif-
ference was found for the pacing mode according 
to the Kaplan-Meier method. Under the assump-
tion of proportional hazard ratios (HR), the Cox 
regression model showed that the following vari-
ables had a significant impact on survival: BMI as 
a continuous variable (HR for one unit decrease 
in BMI: 1.26; 95% CI, 1.05-1.52; P = 0.013), the 
presence of atrial fibrillation (HR 5.58; 95% CI, 
1.20-25.99; P = 0.029), LVEDD (HR for one cm 
increase 2.41, 95% CI, 1.18-4.92; P = 0.016), and 
the absence of arterial hypertension (HR 0.17; 
Table 2. Association between various risk factors and Kaplan-
Meier survival curves calculated by the log-rank test
Variable P
Age (≤median = 67 y vs>median) 0.742
Body mass index (≤median = 26.1 kg/m2 vs>median) 0.024
Ejection fraction (EF):
 EF≤35% vs >35% 0.332
 EF≤25% vs >25% 0.686
Mitral regurgitation 0.272
Left ventricular end-diastolic dimension (LVEDD)
 Four groups by quartiles at 5.7 cm, 6.2 cm, 6.9 cm 0.049
QRS duration (<120 ms vs ≥120 ms) 0.072
NYHA* functional class:
 All four NYHA classes 0.004
 NYHA class<III vs≥III 0.057
Pacing mode 0.129
Indication:
 Ventricular fibrillation; ventricular tachycardia; primary prevention 0.212
 Ventricular fibrillation; ventricular tachycardia 0.119
Atrial fibrillation: 0.030
 Permanent or paroxysmal vs none 0.014
 Permanent vs none 0.005
 Paroxysmal vs none 0.041
Coronary intervention 0.397




Obstructive lung disease 0.961
Arterial hypertension 0.010
Antiarrhythmic medication: 0.464
 Beta blocker vs none 0.927
 Amiodarone vs none 0.466
 Beta blocker and amiodarone vs none 0.969
 Beta blocker vs amiodarone 0.222
Lipid lowering drug 0.223
*NYHA – New York Heart Association.
Figure 2. (A) Kaplan-Meier Estimates of the cumulative probability of 
survival in patients with a body mass index (BMI) below and above the 
median (26.1 kg/m2). The difference in survival between the two groups 
was significant (P = 0.024). (B) Kaplan-Meier cumulative probability of 
survival categorized by absence or presence of atrial fibrillation. The 
three groups differ significantly with respect to survival (P = 0.030). 
The presence of permanent or paroxysmal atrial fibrillation was sig-
nificantly associated with an adverse outcome (P = 0.014).
Croat Med J 2007;48:59-67
64
95% CI, 0.037-0.789; P = 0.024). The resting 
heart rate at baseline had no significant impact 
on survival (P = 0.996). When the effect of BMI 
as a continuous variable was assessed in a multi-
variate Cox regression analysis, which included 
all the variables with a relevant effect on survival, 
the HR resulting from one unit decrease in BMI 
remained significant (P = 0.040) (Figure 3).
Cause of death
Overall, a cardiac cause of death was recorded in 
7 out of 11 patients. Pump failure was the most 
common cause of cardiac death (6 out of 11 pa-
tients). Sudden cardiac death due to incessant 
ventricular tachycardia was noticed in a single 
patient (Table 3). Device examination of the sin-
gle chamber defibrillator revealed that all pro-
grammed therapies were delivered ineffectively in 
this patient, including 4 shocks at maximal out-
put. Re-hospitalization and consecutive in-hos-
pital death were observed in 8 patients, where-
as out-of-hospital death occurred in 3 patients. 
According to clinical circumstances, progressive 
heart failure was the cause of death in 6 patients 
– 4 patients died in the setting of an intensive 
care unit, 1 patient died in a retirement home, 
and 1 at home, with progressive dyspnea. Non-
cardiac deaths occurred in a total of 4 patients. 
One patient with diabetes died due to lower limb 
infection and 1 due to a femur fracture followed 
by several re-operations. One patient, with respi-
ratory distress syndrome, developed irreversible 
multiorgan failure, and 1 patient died due to the 
major intracerebral hemorrhage on oral antico-
agulation.
Discussion
The major findings of this study were that lower 
BMI, presence of atrial fibrillation, NYHA class, 
and absence of arterial hypertension were pre-
dictors of mortality after implantation of cardio-
verter defibrillator. Low BMI in progressive dis-
eases, such as congestive heart failure, was shown 
to be a powerful prognostic marker of poor out-
come and increased mortality (7). To the best of 
our knowledge, it has not been previously stud-
ied whether BMI is associated with the outcome 
of patients implanted with a cardioverter defi-
brillator. In general, obesity, arterial hyperten-
sion, and other components of the metabolic 
syndrome are well known risk factors for the de-
velopment of cardiovascular diseases and associ-
ated with increased mortality over the long-term 
(8,9) However, in large population-based cohort 
studies, a “J” or “U” curve effect was described, in 
which increased mortality was shown not only in 
obese individuals but also in individuals with a 
low BMI (10,11). Horwich et al (12) found sig-
nificantly better survival curves for overweight 
and obese than for underweight patients with 
heart failure. The association between traditional 
cardiovascular risk factors and an adverse clinical 
Figure 3. Crude (top line) and the adjusted hazard ratios (HR; 95% confidence 
intervals marked by whiskers) for one unit decrease in body mass index (BMI) with 
respect to survival. The effect on survival remained significant (P = 0.040) after 
adjustment for other variables with an impact on outcome.
Table 3. Cause of death among the total study population (n = 77)
Cause of death Non-survivors, n (%)
Number of deaths 11 (100)
Cardiac deaths:  7 (64)
 pump failure  6 (55)
 incessant ventricular tachycardia  1 (9)
Non-cardiac deaths:  4 (36)
 sepsis (not device related)  2 (18)
 multiorgan failure  1 (9)
 intracerebral hemorrhage  1 (9)
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outcome in heart failure patients is referred to as 
“reverse epidemiology” or the “obesity paradox” 
(13). Kalantar-Zadeh et al (14) identified differ-
ent possible causes of adverse clinical outcome in 
heart failure, such as the “malnutrition-inflam-
mation complex syndrome,” endotoxin-lipopro-
tein hypothesis, and time discrepancies among 
competitive risk factors. Obese patients may have 
protective alterations in neurohormonal sta-
tus, including sympathetic and renin-angioten-
sin pathways or circulation cytokine levels. Fat 
stores may indicate preserved metabolic efficien-
cy and/or energetic reserves. Lommi et al (15) 
found higher blood ketone bodies as an indicator 
of malnutrition in patients with congestive heart 
failure than in the control group. Depletion of 
liver glycogen favors fatty acid oxidation and ke-
tone body production. Sympathetic stimulation 
and noradrenaline activation, increased secretion 
of tumor necrosis factor and other cytokines, as 
well as an increased cortisol/dehydroepiandros-
terone balance are shown to contribute to the 
malnutrition status (16,17). The findings of the 
present study emphasize that continuous weight 
control of patients treated with defibrillator de-
vices is required. Given the potential morbidity 
and mortality of heart failure in normal to un-
derweight BMI patients, special cardiac training 
programs and nutrition plans may help to pre-
vent progressive weight loss (18).
There is evidence that the presence of low-
er systemic arterial pressure may be an indica-
tor of a poor prognosis in congestive heart fail-
ure (19). In support of this hypothesis, we found 
arterial hypertension in only a minority of non-
survivors, whereas about a half of survivors were 
hypertensive. From a clinical perspective, the 
outcome might have been influenced by the fact 
that obese or normal weight patients with high-
er blood pressure tolerate optimal medical treat-
ment, including angiotensin-converting enzyme 
inhibitors and beta-blockers in adequate doses, 
better than lower weight individuals with pre-ex-
isting arterial hypotension.
Recently, a subgroup analysis performed 
by MADIT II investigators demonstrated that 
BMI≥30 kg/m2 was associated with an increased 
risk of ventricular tachycardia or ventricular fi-
brillation (20). However, there was no relation-
ship between increased BMI and the combined 
end point, including death. In the present study, 
the delivery of appropriate device therapy for 
ventricular tachyarrhythmias was observed in 
more than a half of the defibrillator patients, but 
there was no difference in the frequency of thera-
pies between the group of survivors and non-sur-
vivors. In order to answer the question wheth-
er differences in the outcome were based on the 
type of the implanted device, we performed fur-
ther analysis not only with respect to the device 
type but also to the programmed pacing mode of 
the defibrillator. Significant differences found be-
tween the group of survivors and non-survivors 
according to the pacing mode but not according 
to the device type, a clinically relevant finding. 
However, Kaplan-Meier analysis detected no sig-
nificant impact of the pacing mode on survival. 
It is well known that dual-chamber and especial-
ly single-chamber cardioverter defibrillators are 
ineffective in the treatment of progressive heart 
failure, but very effective in treatment of serious, 
life threatening arrhythmias. In this context, it 
is noteworthy that we avoided right ventricular 
pacing for the conventional device types as much 
as possible, unless there was a clear indication for 
antibradycardia pacing. Nowadays, an increasing 
rate in implantation of cardiac resynchroniza-
tion defibrillators may improve clinical outcome, 
particularly in the subset of patients with severe 
heart failure (21).
In the present study, Kaplan-Meier survival 
curves comparing all four NYHA classes showed 
a highly significant difference. LVEDD catego-
rized by quartiles was weakly significant. The dif-
ference in survival stratified by ejection fraction, 
however, did not reach statistical significance. 
Advanced NYHA functional class and pro-
longed QRS duration seem to be more accurate 
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predictors of mortality, as has been shown previ-
ously (22,23). According to our analysis, the ma-
jority of patients died due to progressive heart 
failure. There is evidence that pump failure is 
more likely the cause of death than malignant ar-
rhythmia in end-stage heart failure (4).
Presence of atrial fibrillation – either perma-
nent or paroxysmal – was associated with high-
er mortality in patients with implantable cardio-
verter defibrillator. In this respect, results of the 
present study are consistent with previous data 
showing that chronic atrial fibrillation is inde-
pendently associated with an increase in mortal-
ity among patients with impaired left ventricular 
function but also in patients without structural 
heart disease (24-26). Deneke et al (27) demon-
strated that the occurrence of paroxysmal atrial 
fibrillation early after cardioverter defibrillator 
implantation was associated with a higher risk 
of death. Parkash et al (28) identified a history of 
atrial fibrillation as one of the valid independent 
predictors of one-year mortality in patients with 
implantable cardioverter defibrillators. Conse-
quently, a clinician has to pay attention to the 
development of atrial fibrillation, which might 
be detected by the electrogram storage capabili-
ties of the device during the follow-up. Strategies 
for adequate rate and/or rhythm control of atri-
al fibrillation, together with oral anticoagulation, 
may help to reduce the overall mortality (29).
Statin therapy has been shown to improve 
the outcome not only in heart failure patients 
but also in the population with implantable car-
dioverter defibrillators, because of its anti-inflam-
matory effect (30,31). Although, more survivors 
than non-survivors were treated with statins, 
we were not able to show significant differences 
in terms of survival because of the limited sam-
ple size. As a shortcoming, only half of the pa-
tients with ischemic cardiomyopathy were actu-
ally treated with statins. In the light of the recent 
data, clinicians should prescribe statin-type hypo-
lipidemic drugs more widely to patients with cor-
onary artery disease and implanted defibrillator.
Some limitations of our study must be tak-
en into account in the interpretation of study re-
sults. First, the total number of patients in this 
study was smaller than in previously published 
defibrillator trials comparing different treatment 
arms. However, our study included non-select-
ed consecutive patients who were representa-
tive of the heterogeneous population followed 
in an outpatient clinic. Second, the limited num-
ber of non-survivors encountered during follow-
up may have reduced the power to detect statis-
tically significant differences for other variables. 
Although the present data suggested that lower 
BMI was associated with a poor outcome in pa-
tients with implantable cardioverter defibrillator, 
further studies are needed to confirm this obser-
vation on larger populations.
In conclusion, the present study demonstrat-
ed that normal to lower BMI, presence of atrial 
fibrillation, absence of arterial hypertension, ad-
vanced NYHA class, and LVEDD were unfa-
vorable predictors for survival in an unselected 
population implanted with cardioverter defibril-
lators. Apart from regular device interrogations, 
high-risk individuals may be identified by the 
above-mentioned characteristics. Continuous 
medical care, particularly with respect to the mul-
tidimensional problems in heart failure, is neces-
sary to improve the prognosis and prevention of 
sudden death.
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